Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.9.4095

Mutation Analysis of IDH1/2 Genes in Unselected De novo Acute Myeloid Leukaemia Patients in India - Identification of A Novel IDH2 Mutation  

Raveendran, Sureshkumar (Division of Cancer Research, Regional Cancer Centre)
Sarojam, Santhi (Division of Cancer Research, Regional Cancer Centre)
Vijay, Sangeetha (Division of Cancer Research, Regional Cancer Centre)
Geetha, Aswathy Chandran (Division of Cancer Research, Regional Cancer Centre)
Sreedharan, Jayadevan (Gulf Medical University)
Narayanan, Geetha (Division of Medical Oncology, Regional Cancer Centre)
Sreedharan, Hariharan (Division of Cancer Research, Regional Cancer Centre)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.9, 2015 , pp. 4095-4101 More about this Journal
Abstract
IDH1/2 mutations which result in alternation in DNA methylation pattern are one of the most common methylation associated mutations in Acute myeloid leukaemia. IDH1/2 mutations frequently associated with higher platelet level, normal cytogentics and NPM1 mutations. Here we analyzed IDH1/2 mutations in 200 newly diagnosed unselected Indian adult AML patients and investigated their correlation with clinical, cytogenetic parameters along with cooperating NPM1 mutation. We detected 5.5% and 4% mutations in IDH1/2 genes, respectively. Except IDH2 c.515_516GG>AA mutation, all the other identified mutations were reported mutations. Similar to reported c.515G>A mutation, the novel c.515_516GG>AA mutation replaces $172^{nd}$ arginine to lysine in the active site of the enzyme. Even though there was a preponderance of IDH1/2 mutations in NK-AML, cytogenetically abnormal patients also harboured IDH1/2 mutations. IDH1 mutations showed significant higher platelet count and NPM1 mutations. IDH2 mutated patients displayed infrequent NPM1 mutations and lower WBC count. All the NPM1 mutations in the IDH1/2 mutated cases showed type A mutation. The present data suggest that IDH1/2 mutations are associated with normal cytogenetics and type A NPM1 mutations in adult Indian AML patients.
Keywords
Acute myeloid leukaemia; IDH1; IDH2; Type A NPM1 mutation;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Abbas S, Lugthart S, Kavelaars FG, et al (2010). Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood, 116, 2122-6.   DOI
2 Ahmad F, Mohota R, Sanap S, et al (2014). Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients. Asian Pac J Cancer Prev, 15, 1247-53.   DOI
3 Ahmad F, Mandava S, Das BR (2009). Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population. Hematol Oncol, 27, 90-7.   DOI   ScienceOn
4 Amary MF, Bacsi K, Maggiani F, et al (2011). IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol, 224, 334-43.   DOI
5 Borger DR, Tanabe KK, Fan KC, et al (2012). Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist, 17, 72-9.   DOI
6 Cairns RA, Iqbal J, Lemonnier F, et al (2012). IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood, 119, 1901-3.   DOI
7 Chotirat S, Thongnoppakhun W, Promsuwicha O, et al (2012). Molecular alterations of Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. J Hematol Oncol, 5, 1-10.   DOI
8 Chou WC, Hou HA, Chen CY, et al (2010). Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood, 115, 2749-54.   DOI
9 Conway O'Brien E, Prideaux S, Chevassut T (2014). The epigenetic landscape of acute myeloid leukemia. Adv Hematol, 2014, 1-15.
10 Dang L, Jin S, Su SM (2010). IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med, 16, 387-397.   DOI
11 Dang L, White DW, Gross S, et al (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 462, 739-44.   DOI   ScienceOn
12 Dohner H, Gaidzik VI (2011). Impact of genetic features on treatment decisions in AML. Hematology Am Soc Hematol Educ Program, 2011, 36-42.   DOI
13 Figueroa ME, Abdel-Wahab O, Lu C, et al (2010). Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell, 18, 553-67.   DOI
14 Ghiam AF, Cairns RA, Thoms J, et al (2012). IDH mutation status in prostate cancer. Oncogene, 31, 3826.   DOI
15 Henegariu O, Heerema NA, Lowe Wright L, et al (2001). Improvements in cytogenetic slide preparation: Controlled chromosome spreading, chemical aging and gradual denaturing. Cytometry, 43, 101-9.   DOI
16 Ho PA, Kopecky KJ, Alonzo TA, et al (2011). Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the children's oncology group and SWOG. Blood, 118, 4561-6.   DOI
17 Im AP, Sehgal AR, Carroll MP, et al (2014). DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia, 28, 1774-83.   DOI
18 Ley TJ, Miller C, Ding L, et al (2013). Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med, 368, 2059-74.   DOI   ScienceOn
19 Losman JA, Kaelin WG Jr (2013). What a difference a hydroxyl makes:mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev, 27, 836-52.   DOI
20 Lin J, Qian J, Yao DM, et al (2011). Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis. Clin Biochem, 44, 779-83.   DOI
21 Marcuccii G, Maharry K, Wu YZ, et al (2010). IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol, 28, 2348-55.   DOI
22 Mardis ER, Ding L, Dooling DJ, et al (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med, 361, 1058-66.   DOI   ScienceOn
23 Parsons DW, Jones S, Zhang X, et al (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321, 1807-12.   DOI   ScienceOn
24 Paschka P, Schlenk RF, Gaidzik VI, et al (2010). IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol, 28, 3636-43.   DOI
25 Patel KP, Ravandi F, Ma D, et al (2011). Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol, 135, 35-45.   DOI
26 Patel JP, Gonen M, Figueroa ME, et al (2012). Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med, 366, 1079-89.   DOI   ScienceOn
27 Patnaik MM, Hanson CA, Hodnefield JM, et al (2012). Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients, Leukemia, 26, 101-5.   DOI
28 Shih AH, Abdel-Wahab O, Patel JP,et al(2012). The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer, 12, 599-612.   DOI
29 Schnittger S, Haferlach C, Ulke M, et al (2010). IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood, 116, 5486-96.   DOI
30 Shaffer LG, McGowan-Jordan J, Schmid M (eds). ISCN 2013: An International System for Human Cytogenetic Nomenclature (2013). Basel, Karger, 2013.
31 Van den Bent MJ, Dubbink HJ, Marie Y, et al (2010). IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European organization for research and treatment of cancer brain tumor group. Clin Cancer Res, 16, 1597-604.   DOI
32 Wagner K, Damm F, Gohring G, et al (2010). Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol, 28, 2356-64.   DOI   ScienceOn
33 Ward PS, Patel J, Wise DR, et al (2010). The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell, 17, 225-34.   DOI   ScienceOn
34 Xu W, Yang H, Liu Y, et al (2011). Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of ${\alpha}$-ketoglutarate-dependent dioxygenases. Cancer Cell, 19, 17-30.   DOI
35 Xu X, Zhao J, Xu Z,et al (2004). Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem, 279, 33946-57.   DOI
36 Zou Y, Zeng Y, Zhang DF, et al (2010). IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochem Biophys Res Commun, 402, 378-83.   DOI   ScienceOn
37 Yamaguchi S, Iwanaga E, Tokunaga K, et al (2014). IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation. Eur J Haematol, 92, 471-7.   DOI
38 Zhang Y, Wei H, Tang K,et al(2012). Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia. Genet Test Mol Biomarkers, 16, 991-5.   DOI
39 Zhang Y, Wei H, Wang M, et al (2011). Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients. Leuk Res, 35, 1301-6.   DOI   ScienceOn